StradBio, Inc.
Developer of engineered cytokine-based immunotherapies using computational protein design, targeted delivery, and engineered conditional-activation systems to increase therapeutic window for oncology and inflammatory/autoimmune indications. The company focuses on de novo designed cytokine mimetics, split-molecule activation strategies, site-specific chemical locking, and preclinical through IND-enabling development.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Precision-tuned de novo cytokine platform
Platform of de novo designed cytokine mimetics with tunable potency intended to modulate immune cell activity while reducing systemic toxicity.
Split-molecule conditional-activation cytokine platform
Split-cytokine approach that requires colocalization of components (logical 'AND' gating) to activate cytokine signaling selectively at target sites.
Site-locked cytokine activation platform
Platform that chemically locks cytokines into an inactive state via site-specific modification; activity is restored upon release of a small-molecule lock in the target microenvironment.
Precision-tuned de novo cytokine platform
Platform of de novo designed cytokine mimetics with tunable potency intended to modulate immune cell activity while reducing systemic toxicity.
Split-molecule conditional-activation cytokine platform
Split-cytokine approach that requires colocalization of components (logical 'AND' gating) to activate cytokine signaling selectively at target sites.
Site-locked cytokine activation platform
Platform that chemically locks cytokines into an inactive state via site-specific modification; activity is restored upon release of a small-molecule lock in the target microenvironment.
Expertise Areas
- Cytokine engineering and immunotherapy
- Computational protein design and de novo protein engineering
- Conditional-activation therapeutics (split-protein and chemically locked systems)
- Preclinical development and IND-enabling studies
Key Technologies
- Computational protein design
- De novo protein design
- Cytokine mimetic engineering
- Split-protein (split-cytokine) AND-gate activation
News & Updates
Conference abstract describing a CD25-targeted de novo IL-2 receptor agonist that selectively expands regulatory T cells; cited on the company site as foundational work for precision-tuned cytokines.
Publication describing a split, conditionally active IL-2 mimetic that reduces systemic toxicity, cited by the company in support of split cytokine technology.
Conference abstract describing a CD25-targeted de novo IL-2 receptor agonist that selectively expands regulatory T cells; cited on the company site as foundational work for precision-tuned cytokines.
Publication describing a split, conditionally active IL-2 mimetic that reduces systemic toxicity, cited by the company in support of split cytokine technology.